GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heron Therapeutics Inc (STU:AXD2) » Definitions » Cyclically Adjusted Price-to-FCF

Heron Therapeutics (STU:AXD2) Cyclically Adjusted Price-to-FCF : (As of Jun. 08, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Heron Therapeutics Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Heron Therapeutics Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Heron Therapeutics's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heron Therapeutics Cyclically Adjusted Price-to-FCF Chart

Heron Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Heron Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Heron Therapeutics's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Heron Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Heron Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Heron Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Heron Therapeutics's Cyclically Adjusted Price-to-FCF falls into.



Heron Therapeutics Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Heron Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Heron Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.058/131.7762*131.7762
=-0.058

Current CPI (Mar. 2024) = 131.7762.

Heron Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.387 100.560 -0.507
201409 -0.517 100.428 -0.678
201412 -0.385 99.070 -0.512
201503 -0.629 99.621 -0.832
201506 -0.460 100.684 -0.602
201509 -0.502 100.392 -0.659
201512 -0.597 99.792 -0.788
201603 -0.823 100.470 -1.079
201606 -0.677 101.688 -0.877
201609 -0.835 101.861 -1.080
201612 -0.946 101.863 -1.224
201703 -0.953 102.862 -1.221
201706 -0.538 103.349 -0.686
201709 -0.628 104.136 -0.795
201712 -0.708 104.011 -0.897
201803 -0.785 105.290 -0.982
201806 -0.738 106.317 -0.915
201809 -0.433 106.507 -0.536
201812 -0.416 105.998 -0.517
201903 -0.577 107.251 -0.709
201906 -0.281 108.070 -0.343
201909 -0.277 108.329 -0.337
201912 -0.312 108.420 -0.379
202003 -0.359 108.902 -0.434
202006 -0.568 108.767 -0.688
202009 -0.399 109.815 -0.479
202012 -0.497 109.897 -0.596
202103 -0.393 111.754 -0.463
202106 -0.534 114.631 -0.614
202109 -0.456 115.734 -0.519
202112 -0.396 117.630 -0.444
202203 -0.400 121.301 -0.435
202206 -0.265 125.017 -0.279
202209 -0.335 125.227 -0.353
202212 -0.301 125.222 -0.317
202303 -0.197 127.348 -0.204
202306 -0.212 128.729 -0.217
202309 -0.064 129.860 -0.065
202312 0.013 129.419 0.013
202403 -0.058 131.776 -0.058

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Heron Therapeutics  (STU:AXD2) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Heron Therapeutics Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Heron Therapeutics's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Heron Therapeutics (STU:AXD2) Business Description

Industry
Traded in Other Exchanges
Address
4242 Campus Point Court, Suite 200, San Diego, CA, USA, 92121
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of SUSTOL, ZYNRELEF, and CINVANTI. Its pipeline product is HTX-011.

Heron Therapeutics (STU:AXD2) Headlines

No Headlines